An Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer: A Narrative Review

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Colorectal cancer is the second most common cancer, representing 13% of all diagnosed cancers. Cetuximab is a recombinant chimeric monoclonal IgG1 antibody and epidermal growth factor receptor (EGFR) inhibitor. Cetuximab is approved for the first-line treatment in combination with chemotherapy or as a single agent in patients who have failed or are intolerant to chemotherapy in patients with EGFR-expressing, RAS wild-type metastatic colorectal cancer. Cetuximab efficacy emerged from studies that were conducted to approve the drug. Cetuximab is well tolerated; its toxicities are caused by its mechanism of action and the most common adverse reaction is skin toxicity. The main purpose of this manuscript is to present an update on the evidence-based summary of efficacy and safety and on the cost-effectiveness of cetuximab. Furthermore, it suggests a management of adverse drug reactions to improve the tolerability of the drug.

Original languageEnglish
Pages (from-to)1497-1509
Number of pages13
JournalAdvances in Therapy
Volume35
Issue number10
DOIs
Publication statusPublished - Oct 1 2018

Fingerprint

Colorectal Neoplasms
Safety
Epidermal Growth Factor Receptor
Proxy
Combination Drug Therapy
Drug-Related Side Effects and Adverse Reactions
Pharmaceutical Preparations
Cost-Benefit Analysis
Neoplasms
Immunoglobulin G
Monoclonal Antibodies
Cetuximab
Drug Therapy
Skin
Therapeutics

Keywords

  • Adverse drug reactions
  • BRAF
  • Cetuximab
  • EGFR
  • Metastatic colorectal cancer

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

An Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer : A Narrative Review. / Fornasier, Giulia; Francescon, Sara; Baldo, Paolo.

In: Advances in Therapy, Vol. 35, No. 10, 01.10.2018, p. 1497-1509.

Research output: Contribution to journalReview article

@article{c5bfbab071544b78948232482251d910,
title = "An Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer: A Narrative Review",
abstract = "Colorectal cancer is the second most common cancer, representing 13{\%} of all diagnosed cancers. Cetuximab is a recombinant chimeric monoclonal IgG1 antibody and epidermal growth factor receptor (EGFR) inhibitor. Cetuximab is approved for the first-line treatment in combination with chemotherapy or as a single agent in patients who have failed or are intolerant to chemotherapy in patients with EGFR-expressing, RAS wild-type metastatic colorectal cancer. Cetuximab efficacy emerged from studies that were conducted to approve the drug. Cetuximab is well tolerated; its toxicities are caused by its mechanism of action and the most common adverse reaction is skin toxicity. The main purpose of this manuscript is to present an update on the evidence-based summary of efficacy and safety and on the cost-effectiveness of cetuximab. Furthermore, it suggests a management of adverse drug reactions to improve the tolerability of the drug.",
keywords = "Adverse drug reactions, BRAF, Cetuximab, EGFR, Metastatic colorectal cancer",
author = "Giulia Fornasier and Sara Francescon and Paolo Baldo",
year = "2018",
month = "10",
day = "1",
doi = "10.1007/s12325-018-0791-0",
language = "English",
volume = "35",
pages = "1497--1509",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Springer Healthcare",
number = "10",

}

TY - JOUR

T1 - An Update of Efficacy and Safety of Cetuximab in Metastatic Colorectal Cancer

T2 - A Narrative Review

AU - Fornasier, Giulia

AU - Francescon, Sara

AU - Baldo, Paolo

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Colorectal cancer is the second most common cancer, representing 13% of all diagnosed cancers. Cetuximab is a recombinant chimeric monoclonal IgG1 antibody and epidermal growth factor receptor (EGFR) inhibitor. Cetuximab is approved for the first-line treatment in combination with chemotherapy or as a single agent in patients who have failed or are intolerant to chemotherapy in patients with EGFR-expressing, RAS wild-type metastatic colorectal cancer. Cetuximab efficacy emerged from studies that were conducted to approve the drug. Cetuximab is well tolerated; its toxicities are caused by its mechanism of action and the most common adverse reaction is skin toxicity. The main purpose of this manuscript is to present an update on the evidence-based summary of efficacy and safety and on the cost-effectiveness of cetuximab. Furthermore, it suggests a management of adverse drug reactions to improve the tolerability of the drug.

AB - Colorectal cancer is the second most common cancer, representing 13% of all diagnosed cancers. Cetuximab is a recombinant chimeric monoclonal IgG1 antibody and epidermal growth factor receptor (EGFR) inhibitor. Cetuximab is approved for the first-line treatment in combination with chemotherapy or as a single agent in patients who have failed or are intolerant to chemotherapy in patients with EGFR-expressing, RAS wild-type metastatic colorectal cancer. Cetuximab efficacy emerged from studies that were conducted to approve the drug. Cetuximab is well tolerated; its toxicities are caused by its mechanism of action and the most common adverse reaction is skin toxicity. The main purpose of this manuscript is to present an update on the evidence-based summary of efficacy and safety and on the cost-effectiveness of cetuximab. Furthermore, it suggests a management of adverse drug reactions to improve the tolerability of the drug.

KW - Adverse drug reactions

KW - BRAF

KW - Cetuximab

KW - EGFR

KW - Metastatic colorectal cancer

UR - http://www.scopus.com/inward/record.url?scp=85053538329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053538329&partnerID=8YFLogxK

U2 - 10.1007/s12325-018-0791-0

DO - 10.1007/s12325-018-0791-0

M3 - Review article

AN - SCOPUS:85053538329

VL - 35

SP - 1497

EP - 1509

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

IS - 10

ER -